癌症患者合并急性心肌梗死（AMI）的治疗仍然具有挑战性。本研究的目的是比较药物洗脱球（DEB）与药物洗脱支架（DES）在这一高危人群中的安全性和效果。在2017年1月1日至2022年1月1日期间，北京朝阳医院收治的AMI患者中进行了回顾性纳入癌症患者。主要终点为主要不良心血管事件（MACE），次要终点包括重度出血事件、心功能不全和心脏并发症。最终纳入164例癌症患者的AMI患者进行最终分析。DEB组患者在中位随访21.8个月期间MACE发生率较DES组低（22.9% vs. 37.1%，p = 0.23）。DEB组患者在重度出血事件发生率方面较DES组趋势低（6.3% vs. 18.1%，HR 2.96，95% CI [0.88, 9.92]，p = 0.08）。两组在心功能不全（4.2% vs. 9.5%，p = 0.32）和心脏并发症（0.0% vs. 2.6%，p = 0.56）发生率方面没有显著差异。本研究结果表明，在AMI患者中，DEB组与DES组相比，重度出血事件发生率趋势较低，MACE发生率数字上较低。© 2023. BioMed Central Ltd.，施普林格自然出版集团的一部分。

Treatment for cancer patients presenting with acute myocardial infarction (AMI) remains challenging. The objective of the study was to investigate the safety and efficiency of drug eluting balloon (DEB) versus drug eluting stent (DES) in this high-risk group.Between 1st January 2017 and 1st January 2022, cancer patients admitted to Beijing Chaoyang Hospital with AMI were retrospectively enrolled. The primary endpoint was major adverse cardiovascular event (MACE). The secondary endpoints included major bleeding events, heart failure and cardiac complications.A total of 164 cancer patients presenting with AMI were included in the final analysis. Patients treated with DEB had a numerically lower rate of MACE than those treated with DES during a median follow-up of 21.8 months (22.9% vs. 37.1%, p = 0.23). Patients treated with DEB had a trend towards lower rate of major bleeding events than patients treated with DES (6.3% vs. 18.1%, HR 2.96, 95% CI [0.88, 9.92], p = 0.08). There were no significant differences between the two groups with regards to the rate of heart failure (4.2% vs. 9.5%, p = 0.32) and cardiac complications (0.0% vs. 2.6%, p = 0.56).The present study demonstrated that in cancer patients with AMI, DEB had a trend towards lower rate of major bleeding events and a numerically lower rate of MACE compared with DES.© 2023. BioMed Central Ltd., part of Springer Nature.